HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Related

450.903

-2.583-0.57%

Number of Gainers:8

Number of Losers:37

Number of Flat:6

PE:- -

High:455.223

Open:453.447

Low:445.681

Close:453.486

Volume:529.76M

Turnover:10.46B

Market Cap:2.85T

Float Cap:1.98T

Loading ...

Meituan's Potential Long-Term Earnings Recovery Seems to be Overlooked

Morgan Stanley Boosts Angelalign Price Target to HK$105 While Raising Working Capital Efficiency Forecast

ANGELALIGN's Triple Growth Strategy: How a Dual-Engine Model and Market Share Gains Are Redefining the Global Orthodontics Landscape

Hong Kong stocks open lower | Hang Seng Index dips 0.19% as pharma stocks rally, gold miners slide, SIMCERE PHARMA jumps nearly 5%

Microport Scientific Says Delay in Publication of Interim Results

Innovent Biologics Grants 583,731 Restricted Shares Under 2024 Share Scheme

China Resources Mixc Lifestyle Services (SEHK:1209) Stock Price Drifts As Margins Hold Firm

Simply Wall St.

Simcere Zaiming Licenses Sim0660 to Roche in Deal Worth up to $1.53 Billion

Zhongsheng Group Holdings (SEHK:881) Stock Slides As Trailing Losses Deepen

Simply Wall St.

Innovent Biologics Files List of Board, Board Committee Members with Disclosure Duties

Fund Manager Trims Stake in KEYMED BIO-B With HK$3.76M Share Sale

Executive Director Wang Yuxiao Reduces Stake in Remegen with Share Sale

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return Reporting Share Repurchase for Cancellation

Tellgen Corporation Secures Six New Medical Device Approvals

Medical Sector Hitting an Earnings Inflection Point? 512170 Ends Green Amid AI4S Boost for HK CXO Stocks

BAIRONG AI-W Repurchases 110,000 Shares for HK$597,100 on September 1

Bairong Files HKEX Next-Day Disclosure Return Reporting 48,425 New Shares Issued Under Incentive Plan

Roche Signs Global Licensing Pact for Simcere's B-Cell Cancer Drug Candidate

Hygeia Healthcare Files HKEX Next-Day Return Disclosing Share Buyback at HKD 10.25

Simcere Pharma Enters Exclusive Global Licensing Pact with Roche for Novel Antibody Asset

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/BK1583/news?page=15"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":450.90295,"timestamp":1789114133774,"preClose":453.48572,"halted":0,"volume":529756888,"delay":0,"changeRate":-0.005695,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-2.582764,"latestTime":"09-11 16:00:00","open":453.44696,"high":455.22345,"low":445.6806,"amount":10457922363,"amplitude":0.021043,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":2.061246,"peRate":43.541097,"turnoverRate":0.004319,"increases":7,"decrements":39,"flats":3,"marketCap":2847092177504,"floatMarketCap":1979517572000},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":455.22345,"amplitude":0.021043,"preClose":453.48572,"low":445.6806,"pbRate":"2.061246","latestPrice":450.90295,"volume":529756888,"delay":0,"open":453.44696,"prevYearClose":503.90085,"prevWeekClose":481.394,"prevMonthClose":473.951,"prevQuarterClose":402.118,"fiveDayClose":481.394,"twentyDayClose":480.55,"sixtyDayClose":406.275,"secType":"PLATE","market":"HK","turnoverRate":0.004319,"peRate":43.541097,"marketCap":2847092177504,"floatMarketCap":1979517572000,"timestamp":1789114133774,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":8,"down":37,"flat":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:15,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664896092","title":"Meituan's Potential Long-Term Earnings Recovery Seems to be Overlooked","url":"https://stock-news.laohu8.com/highlight/detail?id=2664896092","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664896092?lang=en_us&edition=fundamental","pubTime":"2026-09-02 13:56","pubTimestamp":1788328560,"startTime":"0","endTime":"0","summary":"0556 GMT - The potential for Meituan's long-term earnings recovery appears to be overlooked by the market, says Morningstar's Chelsey Tam in a note. The Chinese food-delivery platform's earnings are improving as the delivery price war cools but its stock price performance was lukewarm after its 2Q results, likely due to a disappointing 3Q profit outlook, she says. She notes weak macroeconomics and poor weather are weighing on the travel segment, while Meituan is raising its marketing costs in the instore, hotel and travel segments to compete with rival Douyin. Still, \"we think the market is overly concerned about Meituan's share loss in the in-store businesses,\" she says. Morningstar retains its fair-value estimate at 110 Hong Kong dollars, noting Meituan's shares seem undervalued. Shares rise 1.6% to HK$77.85.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0315178854.USD","LU0348814723.USD","LU2257852520.SGD","LU0821914370.USD","SG9999001689.USD","LU1794554557.SGD","LU1808992512.USD","LU1961090484.USD","LU0251144936.SGD","LU0828237510.HKD","LU0594300179.USD","LU1303224171.USD","LU2152927971.USD","HMTD.SI","LU0819121731.USD","LU0348816934.USD","LU0287142896.SGD","LU0449515922.USD","LU0588545904.SGD","BK1575","LU1868838027.USD","LU0326948709.USD","LU0269904917.USD","LU1720050803.USD","METmain","LU1282648689.USD","LU0345775950.USD","BK1615","LU0039217434.USD","LU0211977185.USD","BK1583","LU2097828557.USD","SG9999002463.SGD","LU0633140727.USD","LU2097828805.USD","LU0543330483.HKD","LU0072913022.USD","LU0165289439.USD","LU0307460666.USD","IE00BF5LJ272.USD","BK1604","LU0672654166.SGD","LU0449509016.USD","IE0032431581.USD","LU0370786039.SGD","LU0828238088.HKD","LU0261950983.USD","LU1048588211.SGD","LU0052750758.USD","LU1675838814.USD","LU2087589342.USD","LU0348825331.USD","LU0499858438.USD","LU0865486749.SGD","LU1770034418.SGD","LU0054237671.USD","LU0594300419.USD","LU0633140560.USD","LU0499858602.USD","LU0417516738.SGD","LU0589944569.HKD","LU1105468828.SGD","LU0588546209.SGD","LU0819123356.HKD","IE0034224299.USD","LU0541501648.USD","LU0320764599.SGD","LU0431992006.USD","LU0577902611.USD","LU0359201885.HKD","LU0878005551.USD","LU2148510915.USD","LU2039709279.SGD","SG9999000459.SGD","LU2778985437.USD","LU1734074674.USD","LU1152091168.USD","LU2242644610.SGD","LU1688375341.USD","LU2488822045.USD","BK1618","IE00BPRC5H50.USD","LU0501845795.SGD","LU1102505762.USD","SG9999002828.SGD","LU1188198961.HKD","LU0117841782.USD","LU0683595622.HKD","LU1328277881.USD","LU0210526637.USD","LU0164872284.USD","LU0029875118.USD","LU1880383440.USD","MPNGY","LU0214875030.USD","LU0196878994.USD","LU1813983027.USD","LU2476274308.USD","BK1233","LU0650527681.SGD","LU0164865239.USD","BK1589","IE00B031HY20.USD","SG9999002562.SGD","LU1807302812.USD","LU0417516902.SGD","LU0871576103.HKD","LU0588545490.SGD","LU1064130708.USD","LU2045819591.USD","LU0359202008.SGD","LU0737861699.HKD","LU0314109678.HKD","LU0456827905.SGD","LU0143863784.USD","LU0540923850.HKD","LU0164880469.USD","LU0359201612.USD","LU0561508036.HKD","LU0067412154.USD","LU0531971595.HKD","LU0577902454.USD","LU0856984785.SGD","LU0047713382.USD","LU0348788117.USD","BK1591","LU0345776255.USD","LU0143863198.USD","LU2226246903.HKD","LU0326950275.SGD","LU0011963245.USD","LU1152091754.HKD","IE00B0JY6N72.USD","LU0868486357.SGD","LU0823426480.USD","LU0541502299.USD","LU0049853897.USD","LU0348805143.USD","LU1224709979.USD","LU1048596156.SGD","LU1481107354.HKD","LU0231483743.USD","LU0509642566.USD","LU0502904849.HKD","LU0149721374.USD","LU0577902298.EUR","LU0588545730.USD","LU1868837565.USD","KWEB","LU0173614495.USD","LU1770036033.HKD","LU1323998911.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU0228659784.USD","SG9999001903.USD","LU1242518857.USD","LU0918141705.HKD","LU0463099449.HKD","LU1868837722.USD","LU0456846285.SGD","LU0823040885.USD","LU0181495838.USD","LU1242518931.SGD","LU0455707207.USD","LU1831875114.USD","LU0327786744.USD","LU0348827113.USD","LU0700851271.USD","LU1880383366.USD","IE00B29SXG58.USD","SG9999000327.SGD","IE00B543WZ88.USD","SG9999014674.SGD","BK1610","LU0043850808.USD","LU0244354667.USD","LU0979878070.USD","LU2097828631.EUR","LU1251922891.USD","LU0132412106.USD","LU0084288322.USD","LU0577902538.SGD","LU0823041008.USD","LU1719994722.HKD","LU0611395673.USD","LU0873338254.USD","LU1328615791.USD","LU0823039010.USD","LU1226287529.USD","BK1521","IE0008368742.USD","LU0634319403.HKD","LU0605514214.HKD","LU0051755006.USD","LU1102505929.USD","LU2125910500.SGD","LU0348735423.USD","LU0577902371.SGD","LU2399975544.HKD","LU0918141887.USD","LU0593848301.USD","LU0823426308.USD","LU0320764755.SGD","LU0048597586.USD","IE00B3M56506.USD","LU2097828714.EUR","03690","LU0797268264.HKD","LU0048580855.USD","LU0054450605.USD","LU1960683339.HKD","LU0572944931.SGD","BK1142","LU0106252389.USD","LU0880133367.SGD","LU0708995583.HKD","LU1064131003.USD","LU0140636845.USD","LU1023057109.AUD","LU1993786604.SGD","LU0828237940.HKD","LU0823038988.USD","LU2097828474.EUR","LU0128522157.USD","IE0008369823.USD","LU2476274720.SGD","LU0072462343.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187348984","title":"Morgan Stanley Boosts Angelalign Price Target to HK$105 While Raising Working Capital Efficiency Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=1187348984","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187348984?lang=en_us&edition=fundamental","pubTime":"2026-09-02 13:52","pubTimestamp":1788328344,"startTime":"0","endTime":"0","summary":"Morgan Stanley has revised its forecasts for Angelalign (06699), raising the company’s price target by 11% to HK$105, up from HK$95, based on a discounted cash flow (DCF) valuation model. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","LU0158827948.USD","LU0053666078.USD","BK4581","LU0106831901.USD","LU1732800096.USD","LU1720051108.HKD","BK1583","IE00B3S45H60.SGD","BK1587","LU0971096721.USD","LU1988902786.USD","LU0882574139.USD","LU2347655156.SGD","BK4504","06699","IE00B775SV38.USD","BK4585","KBWB","BK4534","LU2028103732.USD","LU1244550221.USD","LU0795875169.SGD","LU1363072403.SGD","LU0267386448.USD","LU0795875086.SGD","LU1244550577.SGD","LU2357305700.SGD","LU1162221912.USD","BK4588","BK1100","LU0314104364.USD","LU2111349929.HKD","LU0225283273.USD","LU1791710582.SGD","LU1791710400.SGD","IAI","LU2089284900.SGD","BK1593","LU0158827781.USD","LU0912757837.SGD","LU1074936037.SGD","LU1989772923.USD","LU0390134368.USD","LU2089283258.USD","LU1668664300.SGD","LU2264538146.SGD","IE00BZ1G4Q59.USD","LU1244550494.USD","LU0528227936.USD","LU0006306889.USD","LU1732799900.SGD","LU0106261372.USD","LU1064131342.USD","LU2133065610.SGD","LU0557290698.USD","EWH","LU0098860793.USD","MS","LU0210528500.USD","LU2271345857.HKD","BK4127","LU2487616109.SGD","LU0320765646.SGD","LU1989772840.SGD","BK4516","LU0234570918.USD","LU2023251221.USD","LU1720051017.SGD","LU1548497426.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168301362","title":"ANGELALIGN's Triple Growth Strategy: How a Dual-Engine Model and Market Share Gains Are Redefining the Global Orthodontics Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=1168301362","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168301362?lang=en_us&edition=fundamental","pubTime":"2026-09-02 10:30","pubTimestamp":1788316242,"startTime":"0","endTime":"0","summary":"On August 31, ANGELALIGN (06699) delivered a mid-year report that exceeded market expectations, with its robust operational results and financial metrics signaling a fundamental breakthrough in the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","06699","BK1587","BK1593","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191555999","title":"Hong Kong stocks open lower | Hang Seng Index dips 0.19% as pharma stocks rally, gold miners slide, SIMCERE PHARMA jumps nearly 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191555999","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191555999?lang=en_us&edition=fundamental","pubTime":"2026-09-02 09:43","pubTimestamp":1788313405,"startTime":"0","endTime":"0","summary":"Hong Kong stocks started Tuesday's session on a weak note, with the benchmark Hang Seng Index shedding 0.19% to open at 25,280.82 points. The Hang Seng Tech Index fell 0.41% to 4,532.22 points, while...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664486685","title":"Microport Scientific Says Delay in Publication of Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2664486685","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664486685?lang=en_us&edition=fundamental","pubTime":"2026-09-02 03:18","pubTimestamp":1788290334,"startTime":"0","endTime":"0","summary":"BRIEF-Microport Scientific Says Delay In Publication Of Interim ResultsSept 2 (Reuters)-Microport Scientific Corp0853.HK:DELAY IN PUBLICATION OF 2026 INTERIM RESULTSFurther company coverage:0853.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","00853","BK1583","BK1589","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857975","title":"Innovent Biologics Grants 583,731 Restricted Shares Under 2024 Share Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857975","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664857975?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:49","pubTimestamp":1788274144,"startTime":"0","endTime":"0","summary":"Innovent Biologics grants 583,731 restricted shares under 2024 share schemeInnovent Biologics granted 59,757 share options, exercisable at HK$ 105.76 per share, with a 10-year exercise period.It also ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL8nZgF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU0326950275.SGD","KURE","LU2328871848.SGD","LU0463099449.HKD","LU0502904849.HKD","BK1583","BK1147","01911","LU0455707207.USD","LU1969619763.USD","HK0000165453.HKD","LU2097828714.EUR","LU2097828631.EUR","LU1188198961.HKD","01801","BK1161","LU2242644610.SGD","LU2097828805.USD","LU2097828557.USD","LU0244354667.USD","LU2488822045.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664631168","title":"China Resources Mixc Lifestyle Services (SEHK:1209) Stock Price Drifts As Margins Hold Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2664631168","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664631168?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:21","pubTimestamp":1788272502,"startTime":"0","endTime":"0","summary":"China Resources Mixc Lifestyle Services has a reputation as a rare compounder in China property services, yet the stock slipped in recent weeks with the share price down about 5% over the past three months to HK$38.9 into this H1 2026 report. The headline is that profit quality still does the heavy lifting. Net profit margin sits at 22.3% and basic earnings per share for H1 came in at ¥0.98, both key support pillars for a stock that already trades on an 18.2x P/E.\nIs China Resources Mixc...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9612014-choice2-main-header/1585186781436","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9612014-choice2-main-header/1585186781436"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/real-estate-management-and-development/hkg-1209/china-resources-mixc-lifestyle-services-shares/news/china-resources-mixc-lifestyle-services-sehk1209-stock-price","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/real-estate-management-and-development/hkg-1209/china-resources-mixc-lifestyle-services-shares/news/china-resources-mixc-lifestyle-services-sehk1209-stock-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1258","LU0164939612.USD","LU0051755006.USD","LU0082770016.SGD","LU0456827905.SGD","LU0082770016.USD","LU0620787316.HKD","LU0456846285.SGD","BK1542","01209","BK1229","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859932","title":"Simcere Zaiming Licenses Sim0660 to Roche in Deal Worth up to $1.53 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859932","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859932?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:29","pubTimestamp":1788265777,"startTime":"0","endTime":"0","summary":"Simcere Zaiming licenses SIM0660 to Roche in deal worth up to $1.53 billionSimcere Zaiming, a Simcere Pharmaceutical Group unit, granted Roche exclusive global rights to develop and commercialize tri-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL7pf8YL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664391852","title":"Zhongsheng Group Holdings (SEHK:881) Stock Slides As Trailing Losses Deepen","url":"https://stock-news.laohu8.com/highlight/detail?id=2664391852","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664391852?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:28","pubTimestamp":1788265701,"startTime":"0","endTime":"0","summary":"Hong Kong traders pushed Zhongsheng Group Holdings down to HK$3.93 at Tuesday’s close, extending a rough 90 days for the stock. Yet the latest half year numbers tell a more nuanced story. The company swung from a heavy loss in late 2025 to a modest net profit in the first half of 2026, with basic earnings per share of ¥0.047.\nThe headline is simple: Zhongsheng is still dealing with trailing 12 month losses, but the fresh earnings print hints at a repair job in progress. The key question now...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551705-choice1-main-header/1585186890631","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551705-choice1-main-header/1585186890631"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/retail/hkg-881/zhongsheng-group-holdings-shares/news/zhongsheng-group-holdings-sehk881-stock-slides-as-trailing-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/retail/hkg-881/zhongsheng-group-holdings-shares/news/zhongsheng-group-holdings-sehk881-stock-slides-as-trailing-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","LU0173614495.USD","LU1102505762.USD","BK1520","SG9999001226.SGD","BK1239","00881","BK1589","LU0287142896.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859365","title":"Innovent Biologics Files List of Board, Board Committee Members with Disclosure Duties","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859365","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859365?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:17","pubTimestamp":1788265039,"startTime":"0","endTime":"0","summary":"Innovent Biologics files list of board, board committee members with disclosure dutiesInnovent updated its board and committee roster as of Sept. 1, 2026, naming Yu Dechao as chairman, chief executive","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL3jJnGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","01801","KURE","LU2097828631.EUR","BK1583","LU2242644610.SGD","LU0463099449.HKD","LU1969619763.USD","LU2097828805.USD","LU2488822045.USD","LU0326950275.SGD","LU1188198961.HKD","01911","BK1147","LU0244354667.USD","BK1589","LU2097828714.EUR","LU2097828557.USD","LU2328871848.SGD","BK1161","LU0502904849.HKD","LU2097828474.EUR","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141085303","title":"Fund Manager Trims Stake in KEYMED BIO-B With HK$3.76M Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=1141085303","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141085303?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:50","pubTimestamp":1788263416,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange filings reveal that on August 27, China Universal Asset Management Co., Ltd. reduced its holdings in KEYMED BIO-B (02162) by 48,000 shares.The shares were sold at an average...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02162","BK1161","BK1587","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119974337","title":"Executive Director Wang Yuxiao Reduces Stake in Remegen with Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=1119974337","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119974337?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:44","pubTimestamp":1788263056,"startTime":"0","endTime":"0","summary":"Hong Kong Exchange records show that on August 26, Executive Director Wang Yuxiao sold 6,500 shares of Remegen (09995) at an average price of HK$82 per share, totaling HK$533,000.Following the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","LU1064130708.USD","LU1969619763.USD","BK1574","BK1161","BK0239","688331","BK1583","LU2148510915.USD","LU1064131003.USD","LU2328871848.SGD","09995","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664557078","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return Reporting Share Repurchase for Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2664557078","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664557078?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:43","pubTimestamp":1788262982,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return reporting share repurchase for cancellationZylox-Tonbridge repurchased 53,000 H shares on Sept. 1, 2026 for treasury.Buyback executed on HKEX at H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL1Xjkz2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1574","BK1100","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157462487","title":"Tellgen Corporation Secures Six New Medical Device Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=1157462487","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157462487?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:36","pubTimestamp":1788262589,"startTime":"0","endTime":"0","summary":"Tellgen Corporation (300642.SZ) has announced that the company and its controlling subsidiary, Shanghai Maishi Biotechnology Co., Ltd., recently obtained six medical device registration certificates...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","09996","BK1583","BK0046","159883","300642","BK1574","RSPH","LNGR","LGHT","BK1100","AGNG","GDOC","HART","BK0239","BK0042","MDEV","MEDX","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141380242","title":"Medical Sector Hitting an Earnings Inflection Point? 512170 Ends Green Amid AI4S Boost for HK CXO Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1141380242","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141380242?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:20","pubTimestamp":1788261656,"startTime":"0","endTime":"0","summary":"On September 1st, medical stocks in both A-shares and Hong Kong markets bucked the market's downbeat trend, with related products such as Medical ETF Huabao (512170) and HK Stock Connect Medical ETF...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLHK","HART","BK1583","GDOC","KCAI","LNGR","CXO","WX","MEDX","BK1100","RSPH","159883","BK4585","BK4588","09996","BK1574","AGNG","PTH","512170","IEIH","LGHT","MDEV","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169210649","title":"BAIRONG AI-W Repurchases 110,000 Shares for HK$597,100 on September 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1169210649","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169210649?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:56","pubTimestamp":1788260187,"startTime":"0","endTime":"0","summary":"BAIRONG AI-W (06608) announced that it repurchased 110,000 shares on September 1, 2026, at a total cost of HK$597,100. The buyback was executed at a per-share price ranging from HK$5.385 to HK$5.45.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1131","BK1109","BK1587","BK1575","06608","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853374","title":"Bairong Files HKEX Next-Day Disclosure Return Reporting 48,425 New Shares Issued Under Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853374","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853374?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:45","pubTimestamp":1788259531,"startTime":"0","endTime":"0","summary":"Bairong files HKEX next-day disclosure return reporting 48,425 new shares issued under incentive planBairong filed a next-day disclosure return reporting a repurchase of 110,000 Class B shares at HKD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL8M615G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1131","BK1575","BK1587","06608","BK1109","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664581558","title":"Roche Signs Global Licensing Pact for Simcere's B-Cell Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2664581558","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664581558?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:26","pubTimestamp":1788258389,"startTime":"0","endTime":"0","summary":"Roche signs global licensing pact for Simcere's B-cell cancer drug candidateSept 1 -Chinese drugmaker Simcere Pharmaceutical signed a licensing agreement with Roche on Monday, granting the Swiss pharmaceutical company exclusive global rights to develop, manufacture and commercialise SIM0660, an antibody targeting B-cell cancers.As per deal terms, Simcere is eligible to receive $75 million of upfront payment and up to $1.46 billion in milestone payments.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4N44T0X5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664858319","title":"Hygeia Healthcare Files HKEX Next-Day Return Disclosing Share Buyback at HKD 10.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2664858319","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664858319?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:14","pubTimestamp":1788257645,"startTime":"0","endTime":"0","summary":"Hygeia Healthcare files HKEX next-day return disclosing share buyback at HKD 10.25Hygeia filed a next-day disclosure return reporting a repurchase of 20,000 shares on Sept. 1.Shares were bought on-exc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL2fDwdS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU2488822045.USD","LU0329678337.USD","LU0329678170.USD","BK1209","06078","LU0737861772.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107581220","title":"Simcere Pharma Enters Exclusive Global Licensing Pact with Roche for Novel Antibody Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=1107581220","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107581220?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:06","pubTimestamp":1788257181,"startTime":"0","endTime":"0","summary":"Simcere Pharma (02096) has officially announced the signing of an exclusive licensing agreement with F. Hoffmann-La Roche Ltd (Roche) on September 1, 2026. Under the terms of this agreement, Roche...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":15,"totalSize":383,"code":"91000000","status":"200"}]}}